Inventiva S.A. - American Depository Shares (IVA)
Frequently Asked Questions About Inventiva S.A. - American Depository Shares (IVA)
Has Inventiva S.A. received any regulatory approvals?
As of now, Inventiva S.A. is still in the clinical development phase for its primary candidates. While the company has not yet received full regulatory approval for its drug candidates, it continues to work closely with regulatory authorities to advance its therapies through clinical trials toward eventual approval.
How can I find the latest news and updates from Inventiva?
The latest news and updates from Inventiva S.A. can be found on their official website, where they post press releases, investor presentations, and other relevant information. Additionally, interested parties can follow the company on its social media channels and subscribe to email alerts for real-time updates.
How does Inventiva engage with the investor community?
Inventiva S.A. actively engages with the investor community through regular communications, such as earnings calls, press releases, investor presentations, and participation in industry conferences. This transparency and proactive approach are part of their commitment to keeping shareholders informed about the company's progress and strategic direction.
How does Inventiva prioritize research and development?
Inventiva S.A. prioritizes research and development by focusing resources on its most promising drug candidates and areas of high unmet medical need. The company employs a rigorous selection process for its projects, emphasizing scientific merit, clinical potential, and alignment with their strategic goals.
How does Inventiva S.A. finance its operations?
Inventiva S.A. finances its operations through a combination of equity financing, grants from public institutions, and strategic partnerships. The company has successfully raised capital in the past through public offerings and private placements to fund its clinical trials and research activities.
Is Inventiva S.A. publicly traded?
Yes, Inventiva S.A. is publicly traded on the Nasdaq stock exchange under the ticker symbol IVA. This listing allows investors to buy and sell shares of the company, providing liquidity and access to public markets for funding its ongoing development efforts.
What are American Depository Shares (ADS) and how are they related to Inventiva S.A.?
American Depository Shares (ADS) are negotiable certificates that represent a specified number of shares in a foreign company's stock. For Inventiva S.A., this means that investors can trade shares of the company on the Nasdaq under the ticker symbol IVA, making it accessible to a broader range of investors, particularly in the United States.
What are Inventiva's key areas of focus?
Inventiva S.A. primarily focuses on rare diseases, metabolic disorders, and fibrosis-related conditions. The company is committed to developing innovative therapies that address significant medical needs, leveraging its expertise in small molecules and nuclear receptor biology.
What are Inventiva's lead drug candidates?
Inventiva S.A.'s lead drug candidates include lanifibranor, which is being developed for the treatment of non-alcoholic steatohepatitis (NASH), and other molecules aimed at treating fibrotic diseases. These candidates are at various stages of clinical development, with lanifibranor showing promising results in Phase 2 studies.
What are the risks associated with investing in Inventiva S.A.?
Investing in Inventiva S.A. carries certain risks typical of biopharmaceutical companies, including the uncertainty of clinical trial results, regulatory approvals, competition, and market volatility. Prospective investors should conduct thorough research and consider their risk tolerance when evaluating an investment in the company.
What clinical trials is Inventiva currently conducting?
Inventiva S.A. is actively conducting clinical trials for its lead candidate, lanifibranor, and other product candidates. These trials are designed to evaluate the safety, efficacy, and optimal dosing of their therapies, with a focus on treating conditions such as NASH and related metabolic disorders.
What differentiates Inventiva from its competitors?
Inventiva S.A. differentiates itself through its proprietary expertise in nuclear receptor biology and a strong focus on developing therapies for unmet medical needs in rare and challenging diseases. The company’s innovative drug discovery platform and commitment to high-quality clinical trials set it apart from competitors in the biopharmaceutical sector.
What does Inventiva S.A. do?
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of rare diseases, metabolic disorders, and other serious conditions. The company utilizes its proprietary platform to discover and develop small molecules, particularly those targeting nuclear receptors, which are key regulators in various biological processes.
What is Inventiva's stance on corporate social responsibility?
Inventiva S.A. recognizes the importance of corporate social responsibility (CSR) and is committed to ethical practices, environmental sustainability, and social welfare. The company actively supports initiatives that contribute to the well-being of patients and communities, aligning their business operations with principles of corporate citizenship.
What is Inventiva's vision for the future?
Inventiva S.A.'s vision for the future is to become a leading innovator in the development of novel therapies that address serious medical conditions. The company aims to leverage its scientific expertise and robust pipeline to bring impactful treatments to market, improving patient outcomes and contributing to advancements in healthcare.
What is the management team like at Inventiva?
Inventiva S.A. has a highly experienced management team with deep expertise in the biopharmaceutical industry. The team comprises professionals with backgrounds in drug development, regulatory affairs, finance, and corporate strategy, all of whom are dedicated to advancing the company’s innovative product pipeline.
What partnerships or collaborations does Inventiva have?
Inventiva S.A. has formed strategic partnerships with various pharmaceutical companies and research organizations to enhance its research and development capabilities. These collaborations often focus on sharing expertise, resources, and technologies to accelerate the development of their therapies.
When was Inventiva S.A. founded?
Inventiva S.A. was founded in 2012. Since its inception, the company has grown rapidly, focusing on developing new therapies for unmet medical needs and establishing itself as a significant player in the biopharmaceutical industry.
Where is Inventiva S.A. headquartered?
Inventiva S.A. is headquartered in Daix, France. The company benefits from its location in one of Europe’s leading biotechnology hubs, which facilitates collaboration and innovation within the life sciences sector.
What is the current price of Inventiva S.A. - American Depository Shares?
The current price of Inventiva S.A. - American Depository Shares is 5.900
When was Inventiva S.A. - American Depository Shares last traded?
The last trade of Inventiva S.A. - American Depository Shares was at 2:45 pm EDT on September 29th, 2025